ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1414

Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
Abstract Number: 1415

The Association of Handedness with Radiographic Damage in Patients with Psoriatic Arthritis
Abstract Number: 1416

Structural Damage Progression in the Spine in Patients with Psoriatic Arthritis: Findings from a Longitudinal Cohort Study
Abstract Number: 1417

Common Causes of Hospitalization in Spondyloarthritis Patients: A Nationwide Analysis
Abstract Number: 1418

Impact of Type 2 Diabetes Mellitus on Cardiovascular Outcomes in Patients with Ankylosing Spondylitis on NSAID Therapy
Abstract Number: 1419

Effectivenss of an educational program on non-radiographic axial spondyloarthritis
Abstract Number: 1420

A Nationwide Analysis of In-Hospital Mortality in Adult Ankylosing Spondylitis
Abstract Number: 1421

Impact of Psoriatic Arthritis Disease Activity and Fatigue on Subjective Cognitive Decline (“Brainfog”)
Abstract Number: 1422

Assessment of difficulties, modifications and use of work adaptations in patients with axial spondyloarthritis: validation of the DificuLtAx and ModAL questionnaires
Abstract Number: 1423

Genetic and Cytokine Correlates in Ankylosing Spondylitis: rs27038 polymorphism of ERAP1 gene and IL-17 Interactions : A Case-Control Study
Abstract Number: 1424

Mapping Central Nervous System Responses To Painful Stimuli In Patients With Axial Spondyloarthritis
Abstract Number: 1425

Quantifying Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Long-Term Prospective Cohort
Abstract Number: 1426

Understanding the Drivers of BASDAI and Back Pain Scores in Psoriatic Arthritis
Abstract Number: 1427

Impact of Biologic Therapy on Subclinical Atherosclerosis and Ventricular Function in Psoriatic Arthritis
Abstract Number: 1428

Ankylosing Spondylitis Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].